BASIS-TECHNOLOGIES
28.4.2016 14:03:46 CEST | Business Wire | Press release
Basis Technologies today announces the introduction of Consolidator, a new addition to its extensive range of automation tools. Consolidator performs the technical analysis and merge of SAP ECC systems, including those running on HANA, with minimal user intervention. Automation reduces the risk and cost of the overall process, allowing more businesses to realize the benefits of SAP system consolidation.
A time of change
Sixty-four percent of IT and marketing executives recently surveyed by Gartner said that they expect to transform into a digital business by the end of 20171 .
In such a dynamic, disruptive environment, business initiatives like digital transformation are becoming commonplace. A shift to cloud-based Enterprise Resource Planning (ERP) solutions, including S/4HANA from SAP, is also underway, and M&A activity continues to gather pace. Meanwhile, potentially huge opportunities lurk inside inefficient SAP system landscapes built up over decades of acquisitions and reorganizations.
All of these factors are combining to generate an ever-increasing level of demand for SAP system consolidation projects.
A new way to unlock value
To date, a limited number of tools have been available to support system consolidation. This has resulted in processes which feature an unavoidably high level of manual effort, with the corresponding business risk that such methods naturally bring.
Consolidator offers the chance to automate a critical - and labor-intensive - portion of the consolidation process: the technical merge. Risk and necessary resource inputs are dramatically reduced, enabling businesses to unlock value, focus on innovation, reduce cost of ownership and prepare for a new generation of enterprise solutions.
"Businesses should give more thought to optimization of the SAP systems that enable great customer experiences. Too much cash is being wasted on simply maintaining existing processes and stabilizing legacy infrastructure." said Martin Metcalf, Chief Executive Officer of Basis Technologies. "There is just not enough focus placed on unlocking the latent value within these assets through the use of automation technologies such as Consolidator"
To learn more about Consolidator, visit www.basistechnologies.com/consolidator
About Basis Technologies
Basis Technologies have delivered innovative software solutions for SAP for almost 20 years. We focus on automation tools that enable continuous delivery, helping our customers to keep pace with theirs. Our products support the adoption of methodologies such as Agile and DevOps in an SAP environment, and our client list includes a selection of major multinational companies such as BP, Unilever and Ralph Lauren.
To find out more, visit www.basistechnologies.com .
####
1. Navigate Your Way to Digital Business Transformation With These Resources, Don Scheibenreif, VP Distinguished Analyst, Gartner (August 2015)
2. Consolidator does not support the analysis or merge of transactional or master data. Other tools may be required.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160428005020/en/
Contact:
Basis Technologies
Peter Yabsley
Head of Product Marketing
+44
7867 335 310
peter.yabsley@basistechnologies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom